Group 1 - The core viewpoint of the article is that Lingkang Pharmaceutical (603669) has announced its 2025 annual performance forecast, expecting a net profit attributable to the parent company of approximately -127 million yuan, which represents a reduction in losses of about 2.88% compared to the same period last year [1] Group 2 - The company anticipates a net profit loss for 2025, indicating ongoing financial challenges [1] - The forecast reflects a slight improvement in financial performance compared to the previous year, suggesting potential operational adjustments [1]

Core Viewpoint - Lingkang Pharmaceutical is expected to report a net profit attributable to the parent company of approximately -127 million yuan for the year 2025, representing a reduction in losses of about 2.88% compared to the previous year [1] Financial Performance - The primary reason for the expected loss in 2025 is that the gross profit from sales cannot cover the operating expenses, leading to operational losses [1] - The sales revenue of the anti-infection product category is expected to decline by approximately 70% year-on-year due to the transition period of the centralized procurement policy and price reductions of winning products [1] - Revenue from the cardiovascular product category is anticipated to decrease by around 30% due to increased competition from newly approved products and expanding market demand [1] Operational Challenges - The company is facing pressure on overall profits due to low capacity utilization, which results in higher fixed costs per unit of product, including depreciation and labor [1] - Idle capacity and associated losses are directly impacting the cost structure and profitability of the company [1] Strategic Initiatives - The company is leveraging its sales system advantages to further expand its pharmaceutical agency and distribution business, which has seen significant revenue growth compared to the previous year [1]

格隆汇1月23日丨灵康药业（维权）(603669.SH)公布，公司预计2025年年度实现归属于母公司所有者的 净利润为-12,700万元左右，与上年同期（法定披露数据）相比，减亏2.88%左右；归属于母公司所有者 的扣除非经常性损益的净利润为-14,700万元左右，与上年同期（法定披露数据）相比，减亏18.41%左 右。 ...

| 证券代码：603669 | 证券简称：灵康药业 | 公告编号：2026-003 | | --- | --- | --- | | 债券代码：113610 | 债券简称：灵康转债 | | 灵康药业集团股份有限公司 关于"灵康转债"预计满足转股价格修正条件的提示 性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 灵康药业集团股份有限公司（以下简称"灵康药业"、"公司"）股票 自 2026 年 1 月 12 日至 2026 年 1 月 23 日已有 10 个交易日的收盘价低于当期转 股价格的 85%（5.53 元/股），若未来 20 个交易日内有 5 个交易日收盘价仍继续 满足相关条件，将可能触发"灵康转债"的转股价格向下修正条款。若触发条件， 公司将于触发条件当日召开董事会审议决定是否修正转股价格，并及时履行信息 披露义务。 根据《上海证券交易所上市公司自律监管指引第 12 号——可转换公司债券》 的有关规定，公司可能触发可转换公司债券转股价格向下修正条件的相关情况公 告如下： 一、可转换公司债券的基 ...

证券代码：603669 证券简称：灵康药业 公告编号：2026-002 灵康药业集团股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 业绩预告的适用情形：净利润为负值 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 经公司财务部门初步测算，预计 2025 年年度实现归属于母公司所有者的净 利润为-12,700 万元左右，与上年同期（法定披露数据）相比，减亏 2.88%左右。 预计归属于母公司所有者的扣除非经常性损益的净利润为-14,700万元左右， 与上年同期（法定披露数据）相比，减亏 18.41%左右。 预计 2025 年年度实现营业收入为 36,500 万元左右，与上年同期（法定披露 数据）相比，同比下降 3.89%左右；扣除与主营业务无关的业务收入和不具备商 业实质的收入后的营业收入为 34,500 万元左右，与上年同期（法定披露数据） 相比，同比下降 6.64%左右。 （三）本期 ...

Core Viewpoint - Lingkang Pharmaceutical is expected to report a net profit attributable to shareholders of approximately -127 million yuan for the year 2025, indicating a year-on-year reduction in losses of about 2.88% [1] - The company anticipates a net profit of approximately -147 million yuan after excluding non-recurring gains and losses, reflecting a year-on-year reduction in losses of about 18.41% [1] Group 1: Financial Performance - The primary reason for the expected losses in 2025 is that the sales gross profit cannot cover the period expenses, leading to operational losses [1] - The sales revenue of the anti-infection product category is expected to decline by approximately 70% year-on-year due to the transition period of the centralized procurement policy and price reductions of winning products [1] - The revenue from the cardiovascular product category is projected to decrease by around 30% year-on-year due to increased competition from newly approved products and expanding market demand [1] Group 2: Operational Challenges - The company is facing pressure on overall profits due to low capacity utilization, which results in higher fixed costs per unit of product, including depreciation and labor [1] - Idle capacity and associated losses are directly accounted for in costs, further impacting profitability [1] Group 3: Strategic Initiatives - The company is leveraging its sales system advantages to expand its pharmaceutical agency and distribution business, which has seen significant revenue growth compared to the previous year [1]

| 证券代码：603669 | 证券简称：灵康药业 | 公告编号：2026-001 | | --- | --- | --- | | 债券代码：113610 | 证券简称：灵康转债 | | 灵康药业集团股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 转股情况："灵康转债"自 2025 年 10 月 1 日至 2025 年 12 月 31 日期间， 转股的金额为 1,000 元，因转股形成的股份数量为 153 股，占可转债转股前公司 已发行股份总额的 0.000021%。截至 2025 年 12 月 31 日，累计共有人民币 67,205,000 元"灵康转债"已转换为公司股票，转股数量为 7,806,136 股，占 可转债开始转股前公司已发行股份总额的 1.0942%。 （二）经上海证券交易所自律监管决定书[2020]412 号文同意，公司发行的 525,000,000 元可转换公司债券于 2020 年 12 月 22 日起在上海证券交易所挂牌 交易，债券简称"灵 ...

Core Viewpoint - The company has announced a "Quality Improvement and Efficiency Enhancement Action Plan" aimed at enhancing operational quality, market competitiveness, and investor returns in response to regulatory initiatives and market conditions [1]. Group 1: Operational Focus - The company will concentrate on its core business, aiming to improve operational quality and efficiency by reducing costs and expanding market presence in the "big health" industry [1][2]. - The company plans to leverage opportunities from national procurement policies to increase market share of selected products and ensure stable supply in designated regions [2]. Group 2: Innovation and Product Development - The company aims to strengthen its product line by enhancing research and development capabilities, focusing on high-difficulty generics and innovative drugs, and collaborating with renowned research institutions [4]. - The company will accelerate the launch of new products and optimize resource allocation for ongoing projects, ensuring a dynamic evaluation of existing products for market potential [4]. Group 3: Investor Relations and Returns - The company has distributed a total of 607 million yuan in dividends since its listing in 2015 and plans to enhance investor returns through increased dividend frequency and ratios [5]. - The company emphasizes transparent communication with investors through various channels, including shareholder meetings and performance briefings, to foster a better understanding of its operations [5][6]. Group 4: Governance and Compliance - The company is committed to adhering to regulatory requirements and improving its governance structure to protect the interests of all shareholders, particularly minority investors [6][7]. - The company will enhance the compliance awareness of its key personnel and ensure effective risk management through various supervisory mechanisms [7]. Group 5: Strategic Development - The company will utilize the advantages of the Hainan Free Trade Port to develop a collaborative industrial system and enhance production efficiency through partnerships and contract manufacturing [3]. - The company aims to integrate digital and intelligent technologies into its operations to drive innovation in drug development and production processes [2][3].

（文章来源：证券日报） 证券日报网讯 12月30日，灵康药业发布公告称，公司发布"提质增效重回报"行动方案，提出七项举 措：一、聚焦主责主业，努力提升经营质量和效益；二、强化创新驱动，进一步丰富公司产品线布局； 三、注重投资者回报，共享经营成果；四、提升信披质量，加强投资者关系管理；五、优化公司治理， 提升规范运作水平；六、提升合规意识，强化"关键少数"责任；七、其他说明。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为深入贯彻落实《国务院关于进一步提高上市公司质量的意见》要求，积极 响应上海证券交易所《关于开展沪市公司提质增效重回报专项行动的倡议》，灵 康药业集团股份有限公司（"本公司"或"公司"）结合自身发展战略和实际经营 情况，制定"提质增效重回报"行动方案，以进一步提升公司经营质量和市场竞 争力，增强投资者回报。方案内容如下： 一、聚焦主责主业，努力提升经营质量和效益 证券代码：603669 证券简称：灵康药业 公告编号：2025-079 灵康药业集团股份有限公司 关于"提质增效重回报"行动方案的公告 公司将聚焦主责主业，以市场为导向，提质降本，深挖存量，拓展新量；强 化资本运作，继续加大在"大健康"产业的布局，延伸在"大健康"领域产业链， 加速企业产业升级和市场拓展，提升整体竞争力。 公司积极抢抓新一轮国采及国采到期续约机遇，推动中选国采品种的市场放 量，保障好中选国采品种在中选区域的产品供应；密切关注集中带量采购政策， 做好政策信息的收集和研判，积极响应政策并制定相应策略措施 ...